Quantum BioPharma Ltd. (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial
New agreement moves innovative Lucid-MS treatment from planning into execution. Proprietary platform is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system. Thermo Fisher’s clinical research business is a leading global contract research organization, with impressive expertise in central nervous system and MS studies. Most multiple sclerosis (“MS”) drugs work by quieting the immune system. A new partnership shines the spotlight on a different approach — protecting the nerve’s own insulation — and sets up that treatment for a rigorous clinical test. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative…